title: Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
abstract: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by a specific hybrid gene BCR-ABL (formed as a result of t(9;22)). This leads to two possible mRNA usually present in leukemic cells, either B2A2 or B3A2. Targeting these mRNA by antisense oligonucleotides (AS) might offer the opportunity to decrease leukemic growth. We have tested the ability of AS to inhibit the in vitro proliferation of CD34 positive (CD34+) blood cells from 16 patients with newly diagnosed CML. CD34+ cells were isolated by an immunomagnetic technique and incubated for 16 to 18 hours with an 18 mer AS (0.25 mM). Sense oligonucleotides served as controls. The effects of AS were evaluated by clonogenic test (production of CFU-GM). Moreover, colonies were picked out and studied by RT-PCR to analyse the presence of BCR-ABL transcript. For nine patients with B3A2 transcript, the median inhibition of CFU-GM formation at day 14 was 64.0 +/- 11.2% (68.0 +/- 11.4% at day 21) and for the seven patients with a B2A2 transcript: 59.0 +/- 11.4% (72.5 +/- 12.0% at day 21). AS showed no effect on CD34+ cells from three normal volunteer donor cells. However, for every patient studied, colonies picked out remained BCR-ABL positive with the RT-PCR technique.
authors.affiliation: Laboratoire de Greffe de Moelle, UMR CNRS 5540, Université de Bordeaux II, France.
authors.forename: A
authors.initials: A
authors.lastname: Pigneux
authors.forename: F X
authors.initials: FX
authors.lastname: Mahon
authors.forename: B
authors.initials: B
authors.lastname: Jazwiec
authors.forename: V
authors.initials: V
authors.lastname: Pigeonnier
authors.forename: J
authors.initials: J
authors.lastname: Ripoche
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
mesh_terms: D018952:Antigens, CD34; D002455:Cell Division / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D018390:Gene Targeting; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018952:Antigens, CD34; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl